Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: A meta-analysis

Gene

Volumn 519, Issue 2, 2013, Pages 288-294

  Cao, Hai Yan ^a   Zou, Ping ^a   Zhou, Hao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diffuse large B cell lymphoma; Gene polymorphism; Interleukin 10; Meta analysis

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; INTERLEUKIN 10; THREONINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; LYMPHOMA, LARGE B-CELL, DIFFUSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84875593056     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.01.066     Document Type: Article

References (37)

1. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 1995, 57:289-300.
2. Berglund M., Thunberg U., Roos G., Rosenquist R., Enblad G. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005, 105:4894-4895. (author reply 4895).
3. Bortolin M.T., et al. Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7. Cytokine 2012, 60:90-95.
4. Chen Y., et al. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 2011, 117:585-590.
5. Cunningham L.M., Chapman C., Dunstan R., Bell M.C., Joske D.J. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma 2003, 44:251-255.
6. Davis R.E., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
7. Domingo-Domenech E., et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007, 92:1475-1481.
8. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
9. Fernberg P., et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010, 21:759-769.
10. Gerger A., et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res. Treat. 2010, 119:701-705.
11. Gibson A.W., Edberg J.C., Wu J., Westendorp R.G., Huizinga T.W., Kimberly R.P. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J. Immunol. 2001, 166:3915-3922.
12. Habermann T.M., et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 2008, 112:2694-2702.
13. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
14. Hohaus S., et al. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk. Res. 2009, 33:1352-1356.
15. Iyer S.S., Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 2012, 32:23-63.
16. Kovacs E. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?. Leuk. Res. 2010, 34:912-916.
17. Kube D., et al. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun. 2007, 8:164-167.
18. Kube D., et al. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin. Cancer Res. 2008, 14:3777-3784.
19. Lan Q., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006, 107:4101-4108.
20. Lech-Maranda E., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004, 103:3529-3534.
21. Lech-Maranda E., et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur. Cytokine Netw. 2006, 17:60-66.
22. Liang X.S., et al. Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br. J. Haematol. 2009, 146:418-423.
23. Lossos I.S., Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J. Clin. Oncol. 2006, 24:995-1007.
24. Nacinovic-Duletic A., Stifter S., Dvornik S., Skunca Z., Jonjic N. Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int. J. Lab. Hematol. 2008, 30:230-239.
25. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006, 7:615-624.
26. Purdue M.P., et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007, 28:704-712.
27. Purdue M.P., et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma. Cancer Res. 2011, 71:4898-4907.
28. Rothman N., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006, 7:27-38.
29. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10:170-181.
30. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30:565-610.
31. Skibola C.F., et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am. J. Epidemiol. 2010, 171:267-276.
32. Tesse R., Del Vecchio G.C., De Mattia D., Sangerardi M., Valente F., Giordano P. Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura. Gene 2012, 505:53-56.
33. Thakkinstian A., McElduff P., D'Este C., Duffy D., Attia J. A method for meta-analysis of molecular association studies. Stat. Med. 2005, 24:1291-1306.
34. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech. Bull. 1999, 8:15-17.
35. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 1997, 24:1-8.
36. Wang S.S., et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006, 66:9771-9780.
37. Wang S.S., et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007, 67:5042-5054.